Introduction visit | Phase I | Phase II | 2 Week—daily monitoring phase | |
---|---|---|---|---|
Demographics | ||||
Patient characteristics | Once | – | – | – |
Questionnaires | ||||
ACD | – | Daily | – | Daily |
ACQ | Once | – | Weekly | – |
Medication diary | – | Daily | Weekly | Daily |
Exacerbation question | – | Daily | Weekly | – |
m-AQLQ | Once | End of phase I | Monthly | – |
GA2LEN FFQ | Once | – | End of phase II | – |
HADS | Once | – | – | – |
hEIQ | Once | – | – | – |
SNOT-22 | Once | End of phase I | Monthly | – |
ASQ | – | End of phase I | Biannually | – |
Clinical tests and home-monitoring/mHealth systems | ||||
Allergy test | Once* | – | – | – |
Reversibility test | Once* | – | – | – |
Spirometry | Once | Two times per day | Weekly | Two times per day |
FeNO | Once | Two times per day | Weekly | Two times per day |
Breath temperature | Once | Two times per day | Weekly | Two times per day |
HR and activity level | – | Continuous | Continuous | Continuous |
Respiratory rate | – | Continuous | Continuous | Continuous |
Inhaler usage | – | Continuous | Continuous | Continuous |
Environmental data | – | Continuous | Continuous | Continuous |
*Performed if there is no previous test in medical notes. Atopy will be assessed by skin prick tests,24 or measuring levels of specific IgE in serum. forced expiratory volume in the first second before and after bronchodilation will be assessed using standardised spirometry according to the ERS criteria.25
ACD, Asthma Control Diary; ACQ, Asthma Control Questionnaire; ASQ, After-Scenario Questionnaire; FeNO, fraction of exhaled nitric oxide; GA2LEN FFQ, Global Allergy and Asthma European Network Food frequency Questionnaire; HADS, Hospital Anxiety and Depression Scale; hEIQ, Health Education and Impact Questionnaire; m-AQLQ, mini Asthma Quality of Life Questionnaire; SNOT-22, Sino-Nasal Outcome Test 22.